ISRG
stock Healthcare Medical Instruments & SuppliesOverall Healthy · 62%
- Fundamentals Strong
- Trajectory Steady
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bearish 0 of 5 trend signals bullishRSI 35 — soft momentum, not yet oversold.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $407.29
- +1.24%
- Close
- $407.29
- +1.24%
- Current
- $407.29
- Prev close
- $402.30
- Today
- 2.58M
- 3-mo avg
- 2.11M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 2191 days ago
- Next expected
- Jul 21in 0 days
Recent earnings dates
- Apr 21 91 days ago
- Jan 22 180 days ago
- Jan 14 188 days ago
- Oct 21, 2025 273 days ago
Past earnings dates come from ISRG’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 53d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), ISRG’s fundamentals read as strong overall.
At 49.5x, the price is steep relative to profit; the stock leans heavily on growth that has yet to arrive.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 28.4% margin is strong; the company keeps a healthy slice of every revenue dollar.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 16.0% return on equity is strong; the company compounds owners' capital well.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 14.0% return on assets is strong; the company squeezes good profit from its assets.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 0.14, the company carries less in liabilities than in equity, a conservative balance sheet.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 4.87, short-term assets comfortably cover short-term bills.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 20.5% from the prior year: strong top-line expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 23.0% from the prior year: strong profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 53d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $5.7B | $6.2B | $7.1B | $8.4B | $10.1B |
| Net income | $1.7B | $1.3B | $1.8B | $2.3B | $2.9B |
| Diluted EPS | $4.66 | $3.65 | $5.03 | $6.42 | $7.87 |
| Dividend / share | — | — | — | — | — |
| Total assets | $13.6B | $13.0B | $15.4B | $18.7B | $20.5B |
| Total liabilities | $1.6B | $1.9B | $2.0B | $2.2B | $2.5B |
| Shareholder equity | $12.0B | $11.1B | $13.4B | $16.4B | $17.8B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0B | $2.0B | $2.4B | $2.3B | $2.4B | $2.5B | $2.9B | $2.8B |
| Net income | $526.9M | $565.1M | $685.7M | $698.4M | $658.4M | $704.4M | $794.8M | $821.5M |
| Diluted EPS | $1.46 | $1.56 | $1.89 | $1.92 | $1.81 | $1.95 | $2.19 | $2.28 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 59d ago
- Rosa David J. Chief Executive Officer (CEO) · Director
- Samath Jamie EVP & CFO & Enterprise Technol
- Brosius Mark EVP & Chief Mfg and Supply Cha
- Charlton Henry L EVP & Chief Commercial and Mkt
- Curet Myriam EVP & Chief Medical Officer
- Jeddi Iman SVP & GM da Vinci Platforms &
- Loeb Gary EVP & Chief Legal and Complian
- Wadors Patricia L SVP Chief Human Resources Offi
- Widman Fredrik VP Corporate Controller
- Barratt Craig H Director
- Beery Joseph C Director
- Chew Lewis Director
- Guthart Gary S Director
- Johnson Amal M Director
- Kolli Sreelakshmi Director
- Ladd Amy L Director
- Leonard Keith R Director
- Nachtsheim Jami K Director
- Reed Monica P Director
Officers and board are drawn from ISRG’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 28 Officer or director change reported in an 8-K
- May 11 −6.7% one-day move
- May 8 New 6-month low (-24% off peak)
- May 4 Officer or director change reported in an 8-K
- Apr 22 +7.2% one-day move
- Dec 18, 2025 Officer or director change reported in an 8-K
- Oct 22, 2025 +13.9% one-day move
- Sep 3, 2025 New 6-month low (-22% off peak)
- Sep 3, 2025 −5.9% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 53d ago
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report